SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The community is buzzing around ImmunityBio (IBRX) as founder Dr. Patrick Soon-Shiong appears in highly anticipated prime-time interviews to discuss breakthrough cancer treatments, with investors actively debating the potential for a significant short squeeze and an impactful business update next week that could challenge traditional pharma.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community rallies around the approaching 4/20, emphasizing a long-term "culture coin" vision for the cannabis ecosystem, even as discussions arise regarding its sustainability versus pump-and-dump characteristics.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is generating significant discussion as a bellwether for the U.S. market, with investors observing strong inflows and its proximity to all-time highs. The community is weighing these positive signals against prevailing political and economic uncertainties, prompting ongoing debate about diversification and market direction.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is surging following a strong earnings beat and upbeat guidance for AI/data center demand for its 400G and 800G transceivers, alongside significant analyst price target upgrades. The rally is fueled by short-squeeze momentum and optimism for future growth, though community discussion also reflects concerns over the company's valuation and a recent equity offering.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is trending sharply lower after missing Q4 earnings estimates and providing cautious 2026 guidance, igniting widespread investor frustration and calls for management accountability. Despite the dramatic price drop, some in the community view it as an overreaction and a potential buying opportunity, emphasizing the company's substantial order backlog and the growing demand for energy storage solutions.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after a strong Q4 earnings beat, which included GAAP profitability and robust 2026 guidance driven by numerous new enterprise deals and impressive revenue growth. Despite these positive fundamentals, community sentiment expresses frustration over the stock's flat or declining price, with many blaming market manipulation by a significant short interest while long-term investors accumulate shares, confident in its AI leadership.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is witnessing intense trading and volatility, as the broader AI infrastructure sector reacts to a competitor's recent earnings, prompting strong debate among investors. The community is emphasizing NBIS's robust fundamentals and contrasting it with the perceived weaknesses of its peers.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending amid discussions surrounding its renewed bid to merge NBCUniversal with Warner Bros. Discovery, a strategic move generating debate about its potential to create a media powerhouse or add debt. The impending spin-off of Versant Media Group is also a key talking point, with investors anticipating it will clarify valuation and focus on Comcast's core connectivity and entertainment assets.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc

Aardvark Therapeutics is trending as it halted its Phase 3 trial for ARD-101, its Prader-Willi Syndrome treatment, following reports of reversible cardiac safety signals. The community is actively discussing this significant setback, calling it a disaster and questioning the company's future in the competitive PWS treatment landscape.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is a hot topic amid mixed sentiment following its earnings report, which highlighted robust revenue growth and new defense contracts, but also confirmed a Neutron rocket launch delay into late in the year. While the community is enthusiastic about the company's expanding defense role and broader space industry tailwinds, concerns linger regarding the extended Neutron timeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Aardvark was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial.</li><li>In September, Acadia Pharmaceuticals scrapped development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.</li><li>Soleno Therapeutics’ VYKAT XR is the first approved treatment specifically for hyperphagia in PWS patients.</li></ul><p>Shares of Aardvark Therapeutics (AARD) dived 53% after hours on Friday after the company announced that it is voluntarily pausing its late-stage trial in Prader-Willi Syndrome (PWS).</p><p>The company was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial. Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.</p><h2 class="st-heading-2">Why Is Aardvark Pausing Trial?</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aardvarktherapeutics.com/news-releases/news-release-details/aardvark-therapeutics-announces-voluntary-pause-phase-3-hero">said</a> that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. The company is reviewing the data to determine next steps, it said, while adding that it has also paused enrollment and dosing in the trial as it completes its evaluation.</p><p>The firm also added that it no longer expects data from the trail in the third quarter of 2026.</p><h2 class="st-heading-2">Other Names To Quit PWS Drug Development</h2><p>In September, Acadia Pharmaceuticals <a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">scrapped</a> development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.</p><p>The company then said that intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials and also announced its intent to stop investigating the drug further.</p><h2 class="st-heading-2">Soleno’s Approved Drug</h2><p>Soleno Therapeutics, meanwhile, received FDA approval of VYKAT XR in early 2025, making it the first approved treatment specifically for hyperphagia in PWS patients.</p><p>However, in August, Scorpion Capital revealed a short position against Soleno stock, alleging several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. Scorpion Capital also stated that it intends to submit an emergency Citizen Petition shortly, requesting that the FDA urge Soleno to conduct a voluntary recall of Vykat XR from the market.</p><p>Weeks later, in September, the company <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-stock-tanks-after-patient-treated-with-drug-dies/chwklo0RdHG">stated</a> in a filing with the Securities and Exchange Commission that it is aware of a serious adverse event reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) involving a deceased patient. However, the existence of a report in the data does not establish causation, the company said.</p><p>Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around AARD rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/AARD">AARD stock</a> has dropped 7% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stokes-retail-anticipation-for-breakout-rally/cZTcDCwRITx">SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts 

The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.

Equity

Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline

(RTTNews) - Aardvark Therapeutics Inc. (AARD) announced on Thursday the formation of Ardia Therapeutics Inc., a wholly owned U.S. subsidiary focused on building a dermatology pipeline...

HC Wainwright Reiterates "Buy" Rating for Aardvark Therapeutics (NASDAQ:AARD)

HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Aardvark Therapeutics in a report on Monday...

Aardvark Therapeutics (NASDAQ:AARD) Trading 12% Higher - Time to Buy?

Aardvark Therapeutics (NASDAQ:AARD) Stock Price Up 12% - Should You Buy...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twelve brokerages that are covering the stock, Marketbeat...

Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher - Time to Buy?

Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher - Here's What Happened...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat.com...

HC Wainwright Has Negative Outlook for AARD FY2025 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Research analysts at HC Wainwright reduced their FY2025 earnings estimates for Aardvark Therapeutics in a research note issued to investors...

Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CFO Nelson Sun acquired 3,000 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The stock was purchased...

Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CEO Tien-Li Lee purchased 7,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an...

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Stocktwits

Stocktwits Polls

Concerns over reversible cardiac safety signals at high doses led to a voluntary pause of the Phase 3 HERO trial for its Prader-Willi Syndrome drug.

AARD
Aardvark Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AARD News

AARDAardvark Therapeutics Inc